Sunday February 12, 2017.
Hello and welcome to today’s free report, it’s Sunday the 12th of February.
The subject of today’s report is United Therapeutics, last at $164.08.
While above $155, I believe the next big target is $245, up 49.3% from here.
The company has a record of delivering high returns on equity, which is a mark of a high quality company.
In terms of value, the current share price is a modest multiple of earnings. The trailing PE is just 11.1.
Furthermore, United Therapeutics has no debt at all.
On top of all that, the share price staged a very bullish break when it surpassed the Key Fibonacci Level at $155. As I said earlier, while above $155, the topside target is $245.
Until next time, for Key Levels, I’m Paul Nojin.
Risk Warning – Futures, options, forex, CFD and ETF trading can offer large potential rewards, but can also involve large potential risk. You must be aware of the risks and be willing to accept them in order to trade in these markets. Do not trade with money you cannot afford to lose. This report is general in nature and is not a solicitation to buy or sell. No representation is being made about future results. Proceed at your own risk, and exercise caution at all times. Whenever you have an open position you must also have an active stop loss order to cut losses fast, to protect yourself if the trade fails. It is imperative to minimize risk through the use of stop loss orders.